Hong Kong
· Delayed Price · Currency is HKD Innovent Biologics Company Description
Innovent Biologics, Inc., a biopharmaceutical company, develops and commercializes monoclonal antibodies and other drug assets in the fields of oncology, ophthalmology, autoimmune, and cardiovascular and metabolic diseases in the People’s Republic of China.
It offers Tyvyt, a human anti-PD-1 monoclonal antibody; BYVASDA, a fully-human anti-VEGF monoclonal antibody; HALPRYZA, a recombinant chimeric murine/human anti-CD20 monoclonal antibody; SULINNO, a fully-human antiTNF-α monoclonal antibody; Pemazyre, a selective FGFR inhibitor; Olverembatinib, a novel BCR-ABL TK; Cyramza, a VEGF receptor 2 antagonist; and Retsevmo, a selective and potent RET kinase inhibitor.
The company is also developing IBI-326, a fully-human BCMA CAR T-cell therapy; IBI-376, an oral inhibitor of PI3Kδ; IBI-351, a KRASG12C inhibitor; IBI-344, a repressor of silencing 1/TRK tyrosine kinase inhibitor; IBI-126, an ADC targeting CEACAM5; IBI-306, a novel anti-proprotein convertase subtilisin/kexin type 9 enzyme monoclonal antibody; IBI-362, a glucagon-like peptide-1 receptor/glucagon receptor dual agonist; and IBI-112, a novel long-acting anti-IL-23.
In addition, it develops IBI-110, a novel anti-LAG3 monoclonal antibody; IBI-939, a novel anti-TIGIT monoclonal antibody; IBI-310, an anti-CTLA-4 monoclonal antibody; IBI-323, a novel LAG3/PD-L1 bispecific antibody; IBI-363, a potential PD-1/IL-2 bispecific antibody fusion protein; IBI-343, a recombinant anti-CLDN18.2 monoclonal ADC; and IBI-302, a potential anti-VEGF/complement bispecific fusion protein.
Further, the company develops IBI-128, a late-stage novel non-purine xanthine oxidase inhibitor; IBI-353, a potent and selective, nextgeneration PDE4 inhibitor; and IBI-311, a recombinant anti-IGF-1R monoclonal antibody.
Additionally, it distributes pharmaceutical products; and provides consultation, and research and development services.
Innovent Biologics, Inc. was incorporated in 2011 and is headquartered in Suzhou, the People’s Republic of China.
| Country | Cayman Islands |
| Founded | 2011 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 4,872 |
| CEO | De-Chao Yu |
Contact Details
Address: 168 Dongping Street Suzhou, 215123 China | |
| Phone | 86 512 6956 6088 |
| Website | innoventbio.com |
Stock Details
| Ticker Symbol | 1801 |
| Exchange | Hong Kong Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CNY |
| ISIN Number | KYG4818G1010 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. De-Chao Yu Ph.D. | Co-Founder, Chairman and Chief Executive Officer |
| Hao Xi Ede | Executive Director and Fund Managing Partner |
| Fei You CPA | Chief Financial Officer |
| Vivian Zhang | Chief People Officer, GM and Executive Director |
| Min Liu | Chief Commercial Officer |
| Dongming Wang | Senior Vice President |
| Blake Salisbury | Senior Vice President |
| Dr. Hui Zhou Ph.D. | Senior Vice President |
| Dr. Nageatte Ibrahim M.D. | Oncology Chief Medical Officer |
| Dr. Samuel Suhua Zhang M.B.A., Ph.D. | Global Chief Business Officer |